Xeris Biopharma reported break-even quarterly earnings per share against the Zacks Consensus Estimate of $0.01, improving from a loss of $0.06 per share a year prior. This resulted in an earnings surprise of -100%, while the previous quarter saw a surprise of +66.67%. <\/p>\n
For the quarter ended September 2025, Xeris Biopharma reported revenues of $74.38 million, which exceeded the consensus estimate by 0.04%. This was an increase from the previous year’s revenue of $54.27 million.<\/p>\n
Since the start of the year, Xeris Biopharma shares have risen by approximately 191.2%, compared to the S&P 500’s increase of 15.6%. Ahead of this earnings release, estimate revisions for the company were unfavourable, leading to a Zacks Rank #4 (Sell) for the stock. <\/p>\n
The current consensus EPS estimate for the upcoming quarter is $0.05 on revenues of $81.18 million and -$0.01 on $287.18 million for the current fiscal year. Another industry peer, Assertio, expects to report a quarterly loss of $0.08 per share, marking a year-over-year change of -166.7%, with expected revenues of $26.9 million, down 7.9% from the previous year.<\/p>\n
The recent earnings report for Xeris Biopharma presents a mixed signal for us, with a narrow miss on earnings per share but a beat on revenue. The break-even result, against a projection of a one-cent profit, has created uncertainty following the stock’s massive 191% run-up this year. Implied volatility for XERS options is currently elevated, reflecting market anticipation of a significant price move in the coming days.<\/p>\n
For those of us leaning bearish, the earnings miss could be the catalyst that triggers a correction. Historically, after such a massive run-up like the one we’ve seen in 2025, even a minor disappointment can spark significant profit-taking. Purchasing put options with strike prices 5-10% below the current market price could be a way to capitalize on a potential downturn, especially if management guidance on the earnings call is cautious.<\/p>\n
On the other hand, the strong 37% year-over-year revenue growth provides a compelling bullish counter-argument. This top-line strength suggests solid underlying demand for the company’s products, which could overshadow the minor earnings miss. Selling cash-secured puts is an attractive strategy to collect premium from the heightened volatility, based on the view that strong sales will limit any significant drop in the stock price.<\/p>\n
Given the binary nature of the upcoming management commentary, a non-directional strategy is also warranted. We saw a similar setup with Assertio (ASRT) back in its Q1 2025 report, where the stock moved over 15% after its earnings call. Implementing a long straddle, which involves buying both a call and a put option, would allow a trader to profit from a large price swing in either direction following the call.<\/p>\n","protected":false},"excerpt":{"rendered":"
Xeris Biopharma posts break-even EPS, beats revenue estimates; shares up 191% year-to-date despite negative revisions.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-34229","post","type-post","status-publish","format-standard","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts\/34229","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/comments?post=34229"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/posts\/34229\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/media?parent=34229"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/categories?post=34229"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/sv-eu\/wp-json\/wp\/v2\/tags?post=34229"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}